Evidence map›Paper›PMID 26238017›Full record

ArticleEuropean journal of cancer (Oxford, England : 1990)2015

Venous thromboembolism, interleukin-6 and survival outcomes in patients with advanced ovarian clear cell carcinoma.

Koji Matsuo, Kosei Hasegawa, Kiyoshi Yoshino, Ryusuke Murakami, Takeshi Hisamatsu, Rebecca L Stone, Rebecca A Previs, Jean M Hansen, Yuji Ikeda, Akiko Miyara and 9 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in European journal of cancer (Oxford, England : 1990), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

38 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Article
  5. Review
  6. Unmet Needs and Challenges in Cancer-Associated Venous Thromboembolism.International journal of molecular sciences · 2026
    Review
  7. Article
  8. Review
  9. Article
  10. Review
  11. Pre-treatment thrombocytosis and ovarian cancer survival: A meta-analysis.European journal of obstetrics & gynecology and reproductive biology: X · 2024
    Review
  12. Article
  13. The pathogenesis of cancer-associated thrombosis.International journal of hematology · 2024
    Review
  14. Review
  15. Review
  16. Cancer-associated venous thromboembolism.Nature reviews. Disease primers · 2022
    Review
  17. Article
  18. Article
  19. Review
  20. Mechanisms and biomarkers of cancer-associated thrombosis.Translational research : the journal of laboratory and clinical medicine · 2020
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Koji MatsuoDepartment of Obstetrics and Gynecology, University of Southern California, Los Angeles, CA, USA; Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, USA. Electronic address: koji.matsuo@med.usc.edu.
Kosei HasegawaDepartment of Gynecologic Oncology, Saitama Medical University International Medical Center, Saitama, Japan.
Kiyoshi YoshinoDepartment of Obstetrics and Gynecology, Osaka University Graduate School of Medicine, Osaka, Japan.
Ryusuke MurakamiDepartment of Gynecology and Obstetrics, Kyoto University Graduate School of Medicine, Kyoto, Japan.
Takeshi HisamatsuDepartment of Obstetrics and Gynecology, Osaka University Graduate School of Medicine, Osaka, Japan; Department of Gynecologic Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Rebecca L StoneDepartment of Obstetrics and Gynecology, The Johns Hopkins University, Baltimore, MD, USA.
Rebecca A PrevisDepartment of Gynecologic Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Jean M HansenDepartment of Gynecologic Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Yuji IkedaDepartment of Gynecologic Oncology, Saitama Medical University International Medical Center, Saitama, Japan; Department of Obstetrics and Gynecology, The University of Tokyo Faculty of Medicine, Tokyo, Japan.
Akiko MiyaraDepartment of Gynecologic Oncology, Saitama Medical University International Medical Center, Saitama, Japan.
Kosuke HiramatsuDepartment of Obstetrics and Gynecology, Osaka University Graduate School of Medicine, Osaka, Japan.
Takayuki EnomotoDepartment of Obstetrics and Gynecology, Niigata University Graduate School of Medicine, Niigata, Japan.
Keiichi FujiwaraDepartment of Gynecologic Oncology, Saitama Medical University International Medical Center, Saitama, Japan.
Noriomi MatsumuraDepartment of Gynecology and Obstetrics, Kyoto University Graduate School of Medicine, Kyoto, Japan.
Ikuo KonishiDepartment of Gynecology and Obstetrics, Kyoto University Graduate School of Medicine, Kyoto, Japan.
Lynda D RomanDepartment of Obstetrics and Gynecology, University of Southern California, Los Angeles, CA, USA; Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, USA.
Hani GabraOvarian Cancer Action Research Centre, Department of Surgery and Cancer, Imperial College London, London, UK.
Christina FotopoulouOvarian Cancer Action Research Centre, Department of Surgery and Cancer, Imperial College London, London, UK.
Anil K SoodDepartment of Gynecologic Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Department of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Center for RNA Interference and Non-Coding RNAs, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8M
UNIVERSITY OF TEXAS MD ANDERSON SPORE IN OVARIAN CANCERP50CA083639 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI BAST, ROBERT C · 1999 to 2015
$33.0M
Targeting the PI3K Signaling Pathway in Endometrial CarcinomaP50CA098258 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI BODURKA, DIANE · 2003 to 2020
$32.0M
Training of Academic Gynecologic OncologistsT32CA101642 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI ANIL K SOOD, Kathleen Schmeler · 2005 to 2026
$9.2M
U.T. M. D. Anderson Cancer Center SPORE in Ovarian CancerP50CA217685 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI SOOD, ANIL K · 2017 to 2021
$7.9M
Ovarian Cancer: Mechanisms of Neuroendocrine RegulationR01CA109298 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI SOOD, ANIL K · 2005 to 2017
$4.5M
Platelets promote growth of ovarian cancerR01CA177909 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI AFSHAR-KHARGHAN, VAHID, SOOD, ANIL K · 2013 to 2023
$4.1M
Novel extra cellular RNA-based combinatorial RNA inhibition therapyUH2TR000943 · NCATS · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI CALIN, GEORGE A., LOPEZ-BERESTEIN, GABRIEL · 2013 to 2014
$1.1M
NCATS NIH HHS UH2 TR000943NCATS NIH HHS UH2TR000943NCI NIH HHS CA016672NCI NIH HHS CA109298NCI NIH HHS CA177909NCI NIH HHS P30 CA016672NCI NIH HHS P50 CA083639NCI NIH HHS P50 CA098258NCI NIH HHS P50 CA217685NCI NIH HHS R01 CA109298NCI NIH HHS R01 CA177909NCI NIH HHS T32 CA101642
6 · The paper itself

Abstract

backgroundWe compared survival outcomes and risk of venous thromboembolism (VTE) among patients with advanced and early-stage ovarian clear cell carcinoma (OCCC) and serous ovarian carcinoma (SOC), as well as potential links with interleukin-6 (IL-6) levels.

methodsA multicenter case-control study was conducted in 370 patients with OCCC and 938 with SOC. In a subset of 200 cases, pretreatment plasma IL-6 levels were examined.

findingsPatients with advanced OCCC had the highest 2-year cumulative VTE rates (advanced OCCC 43.1%, advanced SOC 16.2%, early-stage OCCC 11.9% and early-stage SOC 6.4%, P<0.0001) and the highest median levels of IL-6 (advanced OCCC 17.8 pg/mL, advanced SOC 9.0 pg/mL, early-stage OCCC 4.2 pg/mL and early-stage SOC 5.0 pg/mL, P=0.006). Advanced OCCC (hazard ratio [HR] 3.38, P<0.0001), thrombocytosis (HR 1.42, P=0.032) and elevated IL-6 (HR 8.90, P=0.046) were independent predictors of VTE. In multivariate analysis, patients with advanced OCCC had significantly poorer 5-year progression-free and overall survival rates than those with advanced SOC (P<0.01), and thrombocytosis was an independent predictor of decreased survival outcomes (P<0.01). Elevated IL-6 levels led to poorer 2-year progression-free survival rates in patients with OCCC (50% versus 87.5%, HR 4.89, P=0.016) than in those with SOC (24.9% versus 40.8%, HR 1.40, P=0.07).

interpretationAdvanced OCCC is associated with an increased incidence of VTE and decreased survival outcomes, which has major implications for clinical management of OCCC.

Indexed as

AdultAgedBiomarkers, TumorCarcinomaDisease-Free SurvivalDisease ProgressionFemaleHumansIncidenceInterleukin-6JapanKaplan-Meier EstimateMiddle AgedMultivariate AnalysisNeoplasm Recurrence, LocalNeoplasms, Cystic, Mucinous, and SerousBiomarkers, TumorIL6 protein, humanInterleukin-6Clear cell carcinomaIL-6Ovarian cancerSurvival outcomeVenous thromboembolism

Identifiers

PMID26238017
PMCPMC7304744

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.